Advisory - Health Canada suspends licence and requested a recall for PURE75 gel hand sanitizer due to potential serious health risks
OTTAWA, ON, Sept. 23, 2021 /CNW/ -
Summary
Product: PURE75 gel hand sanitizer (NPN 80098346), imported by Haywick Industries.
Issue: The product contains methanol, which may pose serious health risks. The product label is also missing important safety information and directions for use.
What to do: Stop using this product. Consult a health care professional if you have used it and have health concerns. If the product is swallowed, call a poison control centre or seek medical help immediately. Keep all hand sanitizers out of the reach of children.
Issue Health Canada has suspended the product licence for PURE75 gel hand sanitizer (NPN 80098346) due to health risks. The Department tested the product and found that it contains an undeclared impurity, methanol, at elevated levels. Methanol can cause serious health issues and is not authorized for use in hand sanitizers.
Frequent exposure to hand sanitizers containing elevated levels of methanol may cause skin irritation, eye irritation, breathing problems, and headaches. If swallowed, methanol can cause severe adverse reactions, including death.
The product label for PURE75 is also missing important safety information and directions for use, including the following warnings:
Children less than two years of age should not use this product
Supervise children when they use this product
Call a poison control centre and get medical help if product is swallowed
Keep away from open flames and sources of heat; and
Use the product occasionally
A product licence suspension means that it is illegal for any person or company to sell this product in Canada. Health Canada requested that the importer, Haywick Industries, stop selling and recall this product. To date, the company has not complied with this request. In addition, Health Canada suspended Haywick Industries' site licence, which means it cannot manufacture, package, label, or import hand sanitizer products. Health Canada is advising retailers to stop selling this product and consumers to stop using it.
If additional products or safety concerns are identified, Health Canada will take appropriate action and inform Canadians as necessary.
Affected products
PURE75 gel hand sanitizer (NPN 80098346), imported by Haywick Industries
What you should do
Stop using this product.
Follow municipal or regional guidelines on how to dispose of chemicals and other hazardous waste; or
Return the product to your local pharmacy for proper disposal
Consult a health care professional if you have used this product and have health concerns.
Keep all hand sanitizers out of the reach of children.
Never eat or drink hand sanitizers, as swallowing even small amounts can be dangerous or fatal. If swallowed, call a poison control centre or seek medical help immediately.
Genexine (KOSDAQ: 095700), a publicly-listed, clinical-stage Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of serious unmet medical needs, announced a merger with EPD Biotherapeutics...
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period.
The...
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...